Cargando…
Carbamazepine drug reaction involving high fevers during the COVID-19 era
Carbamazepine has demonstrated anticonvulsant properties and is used for a variety of indications in psychiatry and neurology. Total daily doses typically range from 200 to 1200 mg/d, generally divided into 2 doses. Carbamazepine has a broad side-effect profile but is not typically thought to produc...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
College of Psychiatric & Neurologic Pharmacists
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8463002/ https://www.ncbi.nlm.nih.gov/pubmed/34621604 http://dx.doi.org/10.9740/mhc.2021.09.287 |
_version_ | 1784572317360193536 |
---|---|
author | Heyman-Kantor, Reuben Perez, Matthew Phatak, Arti Anderson, Danielle L |
author_facet | Heyman-Kantor, Reuben Perez, Matthew Phatak, Arti Anderson, Danielle L |
author_sort | Heyman-Kantor, Reuben |
collection | PubMed |
description | Carbamazepine has demonstrated anticonvulsant properties and is used for a variety of indications in psychiatry and neurology. Total daily doses typically range from 200 to 1200 mg/d, generally divided into 2 doses. Carbamazepine has a broad side-effect profile but is not typically thought to produce high fevers in the absence of a hypersensitivity syndrome. This is a case of a probable adverse drug reaction to carbamazepine consisting of fever without severe major organ involvement. In this instance, a patient in a manic episode with psychotic features was briefly transferred to a COVID-19 unit to rule out coronavirus infection before the fever resolved. |
format | Online Article Text |
id | pubmed-8463002 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | College of Psychiatric & Neurologic Pharmacists |
record_format | MEDLINE/PubMed |
spelling | pubmed-84630022021-10-06 Carbamazepine drug reaction involving high fevers during the COVID-19 era Heyman-Kantor, Reuben Perez, Matthew Phatak, Arti Anderson, Danielle L Ment Health Clin Case Reports Carbamazepine has demonstrated anticonvulsant properties and is used for a variety of indications in psychiatry and neurology. Total daily doses typically range from 200 to 1200 mg/d, generally divided into 2 doses. Carbamazepine has a broad side-effect profile but is not typically thought to produce high fevers in the absence of a hypersensitivity syndrome. This is a case of a probable adverse drug reaction to carbamazepine consisting of fever without severe major organ involvement. In this instance, a patient in a manic episode with psychotic features was briefly transferred to a COVID-19 unit to rule out coronavirus infection before the fever resolved. College of Psychiatric & Neurologic Pharmacists 2021-09-24 /pmc/articles/PMC8463002/ /pubmed/34621604 http://dx.doi.org/10.9740/mhc.2021.09.287 Text en © 2021 CPNP. The Mental Health Clinician is a publication of the College of Psychiatric and Neurologic Pharmacists. https://creativecommons.org/licenses/by-nc/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Reports Heyman-Kantor, Reuben Perez, Matthew Phatak, Arti Anderson, Danielle L Carbamazepine drug reaction involving high fevers during the COVID-19 era |
title | Carbamazepine drug reaction involving high fevers during the COVID-19 era |
title_full | Carbamazepine drug reaction involving high fevers during the COVID-19 era |
title_fullStr | Carbamazepine drug reaction involving high fevers during the COVID-19 era |
title_full_unstemmed | Carbamazepine drug reaction involving high fevers during the COVID-19 era |
title_short | Carbamazepine drug reaction involving high fevers during the COVID-19 era |
title_sort | carbamazepine drug reaction involving high fevers during the covid-19 era |
topic | Case Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8463002/ https://www.ncbi.nlm.nih.gov/pubmed/34621604 http://dx.doi.org/10.9740/mhc.2021.09.287 |
work_keys_str_mv | AT heymankantorreuben carbamazepinedrugreactioninvolvinghighfeversduringthecovid19era AT perezmatthew carbamazepinedrugreactioninvolvinghighfeversduringthecovid19era AT phatakarti carbamazepinedrugreactioninvolvinghighfeversduringthecovid19era AT andersondaniellel carbamazepinedrugreactioninvolvinghighfeversduringthecovid19era |